Moderna announced first participant dosed in phase 1/2 study of COVID-19 vaccine in Japan led by Takeda
On Jan. 21, 2021, Moderna announced that the first participant has been dosed in the Phase 1/2 study…
On Jan. 21, 2021, Moderna announced that the first participant has been dosed in the Phase 1/2 study…
On Jan. 14, 2021, Twist Bioscience announced that it had started shipping its new synthetic RNA reference controls,…
On Jan. 11, 2021, Moderna announced that it was expanding its pipeline of innovative vaccines with three new…
On Jan. 8, 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) announced it had accepted the recommendation…
On Jan. 8, 2021, BioNTech announced that it was in talks with the European Commission (EC) about an…
On Jan. 7, 2021, Twist Bioscience announced it would supply the U.S. Centers for Disease Control and Prevention…
On Jan. 7, 2021, BioNTech announced publication of preclinical data on its novel mRNA vaccine approach against autoimmune…
On Jan. 6, 2021, Bayer announced it had signed a collaboration and services agreement with CureVac, a biopharmaceutical…
On Jan. 4, 2021, the FDA announced that the two different mRNA vaccines were shown remarkable effectiveness of…
On Dec. 31, 2020, the World Health Organization (WHO) listed the Comirnaty COVID-19 mRNA vaccine for emergency use,…
On Dec. 30, 2020, the National Institutes of Health (NIH) announced that the investigational vaccine known as mRNA-1273…
On Dec. 23, 2020, Moderna announced that Health Canada had authorized its vaccine against COVID-19 for the immunization…
On Dec. 21, 2020, Pfizer and BioNTech announced that the European Commission (EC) had granted a conditional marketing…
On Dec. 19, 2020, Pfizer and BioNTech announced they supplying an additional 100 million doses of COMIRNATY the…
On Dec. 18, 2020, Moderna announced that the European Commission (EC) had exercised its option to purchase an…
On Dec. 18, 2020, Moderna announced that the U.S. Food and Drug Administration (FDA) had authorized the emergency…
On Dec. 17, 2020, Moderna confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological…
On Dec. 17, 2020, XPhyto Therapeutics and 3a-diagnostics announced the successful validation of their point-of-care SARS-CoV-2 (COVID-19) RT-PCR…
On Dec. 16, 2020, BioNTech and Shanghai Fosun Pharmaceutical announced an agreement to supply Mainland China with an…
On Dec. 14, 2020, CureVac announced that it had enrolled the first participant in the pivotal Phase 2b/3…
On Dec. 14, 2020, Moderna confirmed that the Company had concluded an agreement with the Ministry of Health…
On Dec. 11, 2020, Moderna announced that the U.S. government has exercised its option to purchase an additional…
On Dec. 10, 2020, Roche announced a partnership with Moderna to utilise the Elecsys Anti-SARS-CoV-2 S antibody test…
On Dec. 10, 2020, Moderna announced that the first adolescent participants had been dosed in the Phase 2/3…
On Dec. 10, 2020, Pfizer and BioNTech announced that the FDA Vaccines and Related Biological Products Advisory Committee…
On Dec. 9, 2020, Roche announced a partnership with Moderna to utilise the Elecsys Anti-SARS-CoV-2 S antibody test…
On Dec. 8, 2020, Moderna announced the Swiss Federal Government had increased its confirmed order commitment from 4.5…
On Dec. 7, 2020, Moderna announced that the Canadian Government had increased its confirmed order commitment by 20…
On Dec. 3, 2020, Moderna announced in a letter to the editor published in the New England Journal…
On Dec. 2, 2020, Pfizer and BioNTech announced that the Medicines & Healthcare Products Regulatory Agency (MHRA) in…